A new retrospective study, published on Nature, has found that aspirin may help reduce biochemical recurrence (BCR) in prostate cancer patients following robot-assisted radical prostatectomy (RARP).
Analyzing data from over 8,000 patients across 25 centers, researchers observed that aspirin use, after statistical adjustments, was associated with improved 3-year BCR-free survival rates, particularly in high-risk cases with an ISUP grade of 4 or higher. While aspirin’s anti-cancer effects remain a topic of debate, this study suggests it could have a protective role by inhibiting cancer cell proliferation and angiogenesis.
The findings highlight the potential of aspirin as an accessible and cost-effective strategy to improve post-surgical outcomes in prostate cancer, though prospective trials are needed to confirm its effectiveness and determine optimal usage.
Pinostilbene inhibits the Enz-resistant CRPC cell line by inhibiting AR variant 7
Seminal Vesicle Invasion & Senescent tumor cells.